Chemotherapy Plus Best Supportive Care versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

被引:23
作者
Zhong, Chenxi [1 ]
Liu, Hongcheng [2 ]
Jiang, Liyan [3 ]
Zhang, Wei [3 ]
Yao, Feng [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai 200030, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai 200092, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai 200030, Peoples R China
来源
PLOS ONE | 2013年 / 8卷 / 03期
关键词
QUALITY-OF-LIFE; PEMETREXED MAINTENANCE THERAPY; COMBINATION CHEMOTHERAPY; PHASE-III; CISPLATIN; SURVIVAL; MULTICENTER; STATISTICS; DOCETAXEL; MITOMYCIN;
D O I
10.1371/journal.pone.0058466
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: The use of chemotherapy has been proposed to increase the effectiveness of best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC). Previous trials reported inconsistent findings regarding the efficacy and safety of chemotherapy on overall survival (OS) and treatment-related mortality. We performed a systematic review and meta-analysis to evaluate the effects of chemotherapy plus BSC versus BSC alone on survival of patients with NSCLC. Methodology and Principal Findings: We systematically searched PubMed, EmBase, and the Cochrane Central Register of Controlled Trials for relevant literature. All eligible studies included patients with NSCLC who had received chemotherapy and BSC or BSC alone. All eligible studies measured at least 1 of the following outcomes: OS or treatment-related mortality. Overall, patients that received chemotherapy plus BSC had significant longer OS than those that received BSC alone (HR, 0.76; 95%CI, 0.69-0.84; P<0.001). Additionally, chemotherapy plus BSC as compared to BSC alone resulted in a 28% RR reduction (95%CI: 12-40; P = 0.001) in 6-month mortality, 11% RR reduction (95%CI: 8-15; P<0.001) in 12-month mortality, and 5% RR reduction (95%CI: 1-8; P = 0.02) in 2-year mortality. Toxicity was greater in patients that received chemotherapy plus BSC. Conclusion/Significance: Chemotherapy plus BSC increased the OS and reduced the 6-month, 12-month, and 2-year mortality of NSCLC patients.
引用
收藏
页数:9
相关论文
共 39 条
[1]   The interpretation of random-effects meta-analysis in decision models [J].
Ades, AE ;
Lu, G ;
Higgins, JPT .
MEDICAL DECISION MAKING, 2005, 25 (06) :646-654
[2]  
AISNER J, 1981, CANCER TREAT REP, V65, P979
[3]   Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].
Anderson, H. ;
Hopwood, P. ;
Stephens, R. J. ;
Thatcher, N. ;
Cottier, B. ;
Nicholson, M. ;
Milroy, R. ;
Maughan, T. S. ;
Falk, S. J. ;
Bond, M. G. ;
Burt, P. A. ;
Connolly, C. K. ;
McIllmurray, M. B. ;
Carmichael, J. .
BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453
[4]  
[Anonymous], COCHRANE DATABASE SY
[5]   Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis [J].
Baggstrom, Maria Q. ;
Stinchcombe, Thomas E. ;
Fried, Daniel B. ;
Poole, Charles ;
Hensing, Thomas A. ;
Socinski, Mark A. .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (09) :845-853
[6]   Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial [J].
Belani, Chandra Prakash ;
Wu, Yi-Long ;
Chen, Yuh-Min ;
Kim, Joo-Hang ;
Yang, Sung-Hyun ;
Zhang, Li ;
Peterson, Patrick ;
Orlando, Mauro .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (03) :567-573
[7]   CISPLATIN CYCLOPHOSPHAMIDE MITOMYCIN COMBINATION CHEMOTHERAPY WITH SUPPORTIVE CARE VERSUS SUPPORTIVE CARE ALONE FOR TREATMENT OF METASTATIC NON-SMALL-CELL LUNG-CANCER [J].
CARTEI, G ;
CARTEI, F ;
CANTONE, A ;
CAUSARANO, D ;
GENCO, G ;
TOBALDIN, A ;
INTERLANDI, G ;
GIRALDI, T .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (10) :794-800
[8]   A RANDOMIZED TRIAL OF ALTERNATING CHEMOTHERAPY VERSUS BEST SUPPORTIVE CARE IN ADVANCED NON-SMALL-CELL LUNG-CANCER [J].
CELLERINO, R ;
TUMMARELLO, D ;
GUIDI, F ;
ISIDORI, P ;
RASPUGLI, M ;
BISCOTTINI, B ;
FATATI, G .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) :1453-1461
[9]   Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [J].
Ciuleanu, Tudor ;
Brodowicz, Thomas ;
Zielinski, Christoph ;
Kim, Joo Hang ;
Krzakowski, Maciej ;
Laack, Eckart ;
Wu, Yi-Long ;
Bover, Isabel ;
Begbie, Stephen ;
Tzekova, Valentina ;
Cucevic, Branka ;
Pereira, Jose Rodrigues ;
Yang, Sung Hyun ;
Madhavan, Jayaprakash ;
Sugarman, Katherine P. ;
Peterson, Patrick ;
John, William J. ;
Krejcy, Kurt ;
Belani, Chandra P. .
LANCET, 2009, 374 (9699) :1432-1440
[10]   Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) [J].
Cohen, Martin H. ;
Cortazar, Patricia ;
Justice, Robert ;
Pazdur, Richard .
ONCOLOGIST, 2010, 15 (12) :1352-1358